Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Massachusetts
Clinical trial register · United States · industry-sponsored

Clinical Trials in Massachusetts, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC
9144
Studies in scope
industry-sponsored, all four open statuses
4957
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 5309 Florida 4445 Illinois 2491 Georgia 2363 Arizona 2246
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca67 Novartis Pharmaceuticals66 Eli Lilly and Company52 AbbVie39 Bristol-Myers Squibb35
State
California5309 Florida4445 Illinois2491 Georgia2363 Arizona2246
All 51 states
Target enrolment
to

Trials with a site in Massachusetts

1830 of 9144 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Active, closed
AstraZeneca
Phase 3
893
Arizona, California, Colorado, Connecticut, Delaware, Kentucky, Maryland, Massachusetts
2021-05-10
Recruiting
Sellas Life Sciences Group
Phase 1/2
160
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Massachusetts
2021-05-10
Recruiting
Debiopharm International SA
Phase 1
464
California, Connecticut, Florida, Massachusetts, Michigan, Minnesota, Missouri, New York
2021-04-30
Active, closed
C4 Therapeutics, Inc.
Phase 1
224
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Minnesota, Missouri
2021-04-27
Recruiting
Alnylam Pharmaceuticals
Observational
150
Alabama, Arizona, California, Maryland, Massachusetts, Minnesota, New York, North Carolina
2021-04-26
Recruiting
Day One Biopharmaceuticals, Inc.
Phase 2
141
California, District of Columbia, Illinois, Maryland, Massachusetts, Michigan, Missouri, New York
2021-04-22
Recruiting
GlaxoSmithKline
Phase 2
37
Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, New Jersey
2021-04-16
Recruiting
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
NCT04580420Primary Hyperoxaluria Type 1, End Stage Renal Disease
DrugDcr-Phxc
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Phase 2
28
California, Massachusetts, Minnesota, New York
2021-04-15
Recruiting
ModernaTX, Inc.
Phase 1/2
77
California, Florida, Illinois, Maryland, Massachusetts, Michigan, New York, North Carolina
2021-04-15
Active, closed
IDEAYA Biosciences
Phase 1
169
Arizona, Arkansas, California, Florida, Indiana, Maryland, Massachusetts, New York
2021-04-14
Active, closed
Beacon Therapeutics
Phase 2
14
Florida, Massachusetts, Ohio, Oregon, Texas
2021-04-13
Active, closed
COMPASSION S3 Post-Approval Study
NCT04860765Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration
Edwards Lifesciences
Observational
150
Alabama, California, Colorado, Illinois, Massachusetts, Minnesota, Missouri, New Jersey
2021-04-13
Active, closed
ALX Oncology Inc.
Phase 2
189
California, Florida, Georgia, Illinois, Maryland, Massachusetts, New Jersey, New York
2021-04-02
Recruiting
A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes
NCT04786262Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
DrugZimislecel
Vertex Pharmaceuticals Incorporated
Phase 3
57
California, Florida, Illinois, Maryland, Massachusetts, Pennsylvania, Texas, Virginia
2021-03-29
Recruiting
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
NCT04634916Kidney Disease, End-Stage, End-stage Renal Disease, Arteriovenous Fistula
C. R. Bard
Not applicable
220
California, Florida, Massachusetts, New York, North Carolina, Ohio, Pennsylvania, Tennessee
2021-03-26
Recruiting
Guerbet
Phase 4
2,076
Arizona, Connecticut, Illinois, Massachusetts, Missouri, North Carolina, Pennsylvania, Texas
2021-03-24
Recruiting
Vivace Therapeutics, Inc
Phase 1/2
434
California, Illinois, Massachusetts, Minnesota, New York, Texas, Virginia
2021-03-24
Active, closed
Hoffmann-La Roche
Phase 3
751
Alabama, Arizona, California, District of Columbia, Florida, Indiana, Kansas, Massachusetts
2021-03-24
Active, closed
Bristol-Myers Squibb
Phase 1/2
216
California, Florida, Louisiana, Massachusetts, Michigan, New Jersey, North Carolina, Pennsylvania
2021-03-22
Active, closed
Kiniksa Pharmaceuticals International, plc
Observational
500
Alaska, Arizona, California, Illinois, Iowa, Maryland, Massachusetts, Michigan
2021-03-16
Recruiting
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
NCT04555161Pulmonary Arterial Hypertension, Pulmonary Hypertension, Right Heart Dysfunction
Aria CV, Inc
Not applicable
30
California, Indiana, Massachusetts, Minnesota, New York, Ohio, South Carolina, Wisconsin
2021-03-15
Active, closed
Atrasentan in Patients With Proteinuric Glomerular Diseases
NCT04573920IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease
DrugAtrasentan
Novartis Pharmaceuticals
Phase 2
103
California, Colorado, Louisiana, Massachusetts, Minnesota, Nevada, North Carolina, Texas
2021-03-15
Active, closed
Molnlycke Health Care AB
Not applicable
44
Arizona, California, District of Columbia, Florida, Massachusetts, Pennsylvania
2021-03-10
Recruiting
Calico Life Sciences LLC
Phase 1
248
Arizona, Connecticut, Maryland, Massachusetts, Michigan, New York, North Carolina, Pennsylvania
2021-03-09
Active, closed
BPGbio
Observational
150
Massachusetts
2021-03-01
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
DrugsTNO155·Opnurasib·Tislelizumab
Novartis Pharmaceuticals
Phase 1/2
344
Georgia, Massachusetts, Pennsylvania, Texas
2021-02-24
Active, closed
AbbVie
Phase 1
81
Massachusetts, Missouri, North Carolina, Rhode Island, Texas, Virginia
2021-02-23
Active, closed
Hoffmann-La Roche
Phase 3
270
Alabama, California, Florida, Maryland, Massachusetts, Mississippi, New Jersey, New York
2021-02-23
By invitation
Abeona Therapeutics, Inc
Observational
22
California, Massachusetts
2021-02-09
Active, closed
Taiho Oncology, Inc.
Phase 1/2
101
California, Connecticut, Florida, Illinois, Indiana, Massachusetts, Missouri, New Jersey
2021-02-09
Active, closed
Anthos Therapeutics, Inc.
Phase 2
1,287
Alabama, Connecticut, Florida, Georgia, Kentucky, Maryland, Massachusetts, Michigan
2021-02-02
Recruiting
AB Science
Phase 3
495
Alabama, California, Kentucky, Maryland, Massachusetts, Virginia
2021-02-02
Active, closed
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
277
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2021-02-02
Active, closed
Stoke Therapeutics, Inc
Phase 2
60
California, Colorado, District of Columbia, Florida, Illinois, Iowa, Massachusetts, Michigan
2021-01-20
Active, closed
Pfizer
Phase 3
257
Florida, Kansas, Massachusetts, Ohio, Tennessee
2021-01-15
Active, closed
Growth Trial: Study of the Renata Minima Stent
NCT05086016Coarctation of the Aorta, Pulmonary Artery Stenosis
Renata Medical
Not applicable
42
California, Massachusetts, Ohio, Tennessee, Washington
2021-01-14
Recruiting
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
NCT04150042Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation, Pancreatic Acinar Cell Carcinoma
DrugsVitamin C·Melphalan
General Oncology, Inc.
Phase 1
24
Massachusetts, New York
2021-01-13
Active, closed
BioNTech SE
Phase 2/3
358
California, Connecticut, District of Columbia, Florida, Georgia, Kentucky, Massachusetts, New Mexico
2021-01-07
Recruiting
Daiichi Sankyo
Observational
30
California, Massachusetts, New York, Ohio, Texas
2021-01-07
Recruiting
Dynocardia, Inc
Observational
91
Massachusetts
2021-01-01
Active, closed
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
NCT04639219Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
102
California, Indiana, Massachusetts, New Jersey, New York, Texas, Virginia
2020-12-30
Recruiting
Collection of Samples USOPTIVAL Study
NCT04792684Colorectal Cancer (CRC), Advanced Adenomas (AA)
Universal Diagnostics
Observational
1,300
California, Florida, Illinois, Louisiana, Massachusetts, New York, Pennsylvania, Tennessee
2020-12-30
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2
182
California, Colorado, District of Columbia, Florida, Massachusetts, Michigan, Minnesota, Mississippi
2020-12-18
Active, closed
Neurocrine Biosciences
Phase 3
182
California, Colorado, Georgia, Indiana, Maryland, Massachusetts, Michigan, Minnesota
2020-12-16
Recruiting
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
NCT04683250RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors
Taiho Pharmaceutical Co., Ltd.
Phase 1/2
244
California, Massachusetts, Michigan, New York, Tennessee, Texas
2020-12-16
Active, closed
AstraZeneca
Phase 3
358
California, Massachusetts, New Hampshire, New York, Texas, Virginia, Washington
2020-12-16
Active, closed
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1/2
232
California, Colorado, Massachusetts, Michigan, New York, Ohio, Oregon, Tennessee
2020-12-14
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Alabama, California, Florida, Georgia, Illinois, Indiana, Kentucky, Massachusetts
2020-12-11
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
612
California, Florida, Illinois, Massachusetts, Michigan, New York, Ohio, Pennsylvania
2020-12-08
Active, closed
MeiraGTx Ocular UK Ltd
Phase 3
97
California, Florida, Georgia, Massachusetts, Michigan, North Carolina, Pennsylvania, Texas
2020-12-04
Active, closed
Amgen
Phase 3
135
California, Georgia, Maryland, Massachusetts
2020-12-04
Recruiting
W.L.Gore & Associates
Not applicable
133
Arizona, California, Florida, Georgia, Kentucky, Maryland, Massachusetts, Nebraska
2020-12-03
Active, closed
Hoffmann-La Roche
Phase 3
769
Alabama, Arizona, California, Colorado, Florida, Kentucky, Maryland, Massachusetts
2020-12-03
Active, closed
PARADIGM: Amplatzer Valvular Plug for PVL Closure
NCT04489823Paravalvular Aortic Regurgitation
Abbott Medical Devices
Not applicable
200
Alabama, Georgia, Massachusetts, Minnesota, Missouri, Nebraska, New Jersey, New York
2020-12-01
Active, closed
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
NCT04623541Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
DrugsEpcoritamab·Pirtobrutinib·Lenalidomide·Venetoclax
Genmab
Phase 1/2
194
Alabama, California, Florida, Maryland, Massachusetts, Michigan, New Jersey, New York
2020-11-25
Recruiting
Alnylam Pharmaceuticals
Observational
1,500
California, Florida, Iowa, Kansas, Maryland, Massachusetts, New York, North Carolina
2020-11-23
Active, closed
AbbVie
Phase 2
139
Arizona, California, Georgia, Illinois, Maryland, Massachusetts, Nevada, New Jersey
2020-11-20
Active, closed
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
NCT04603001Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
DrugsLY3410738·Azacitidine·Venetoclax
Eli Lilly and Company
Phase 1
260
California, Florida, Illinois, Massachusetts, New York, North Carolina, Tennessee, Texas
2020-11-19
Active, closed
AstraZeneca
Phase 3
957
California, Florida, Indiana, Kentucky, Massachusetts, New York, Tennessee, Texas
2020-11-17
Active, closed
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
NCT04499248Open-angle Glaucoma, Ocular Hypertension
AbbVie
Phase 1/2
100
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Massachusetts
2020-11-16
Active, closed
AstraZeneca
Phase 1/2
702
Massachusetts, New York, Oklahoma, Texas
2020-11-12
Active, closed
MeiraGTx, LLC
Observational
22
California, Massachusetts, North Carolina
2020-11-12
Active, closed
Prevail Therapeutics
Phase 1/2
35
Florida, Massachusetts, Pennsylvania
2020-11-09
Recruiting
Genentech, Inc.
Phase 2
99
California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Massachusetts, Michigan
2020-11-06
Active, closed
Sera Prognostics, Inc.
Not applicable
6,500
California, Connecticut, Delaware, Florida, Kentucky, Louisiana, Massachusetts, Michigan
2020-11-06
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
281
Arizona, California, Florida, Indiana, Louisiana, Maryland, Massachusetts, Michigan
2020-11-03
Active, closed
Genmab
Phase 1/2
543
Alabama, California, Massachusetts, Michigan, New Jersey, New York, North Carolina, Texas
2020-11-03
Active, closed
The Smart Pump Study
NCT04465201Cardiac Output
Abiomed Inc.
Not applicable
35
Louisiana, Massachusetts, Michigan, New York
2020-11-02
Active, closed
Novartis Pharmaceuticals
Phase 2
134
California, Florida, Massachusetts, Minnesota, New York, Pennsylvania, Texas
2020-10-30
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
DrugsRezatapopt·Keytruda·Pembrolizumab
PMV Pharmaceuticals, Inc
Phase 1/2
300
California, Colorado, Connecticut, Delaware, Florida, Massachusetts, Michigan, New York
2020-10-29
Recruiting
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
NCT04516447Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
DrugsAzenosertib·Pegylated liposomal doxorubicin·Gemcitabine·Paclitaxel
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1
172
Colorado, Massachusetts, Missouri, New York, North Carolina, Rhode Island, Tennessee, Texas
2020-10-26
Active, closed
Nyxoah S.A.
Not applicable
115
Alabama, Florida, Georgia, Indiana, Iowa, Massachusetts, New York, Ohio
2020-10-14
Active, closed
Restorbio Inc.
Phase 2
60
Connecticut, Massachusetts
2020-10-13
Active, closed
Hoffmann-La Roche
Phase 3
992
California, Colorado, Florida, Hawaii, Maryland, Massachusetts, Missouri, New Jersey
2020-10-09
Active, closed
Impella ECP Early Feasibility Study
NCT04477603High-risk Percutaneous Coronary Intervention
Abiomed Inc.
Not applicable
100
Massachusetts, Michigan, New Jersey, Ohio
2020-10-09
Active, closed
AstraZeneca
Phase 3
370
Arizona, Illinois, Kansas, Massachusetts, Michigan, Minnesota, Missouri, Nevada
2020-10-02
Active, closed
GlaxoSmithKline
Phase 3
302
Arizona, Florida, Massachusetts, Missouri, Tennessee
2020-10-01
Active, closed
Eli Lilly and Company
Phase 1
200
Arizona, California, Florida, Illinois, Indiana, Maryland, Massachusetts, Minnesota
2020-10-01
Recruiting
Cabaletta Bio
Phase 1/2
40
California, Connecticut, Illinois, Iowa, Massachusetts, New York, North Carolina, Pennsylvania
2020-09-29
Active, closed
Ipsen
Phase 3
161
Arizona, California, Colorado, Connecticut, Florida, Georgia, Kansas, Massachusetts
2020-09-24
Active, closed
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT04557449Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung
DrugsAtirmociclib·Midazolam
Pfizer
Phase 2
362
California, Connecticut, Massachusetts, Michigan, Tennessee, Texas
2020-09-23
Recruiting
ImmVira Pharma Co. Ltd
Phase 1/2
30
Arizona, Massachusetts, Pennsylvania, Texas, Virginia
2020-09-17
Active, closed
PF-07104091 as a Single Agent and in Combination Therapy
NCT04553133Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
DrugsPF-07104091·Palbociclib·Letrozole·Fulvestrant
Pfizer
Phase 2
157
Iowa, Kentucky, Massachusetts, New Jersey, New York, Virginia
2020-09-16
Active, closed
Hoffmann-La Roche
Phase 1/2
210
Arizona, California, Massachusetts, Michigan, North Carolina, Texas
2020-09-03
Active, closed
AbbVie
Phase 2
146
Arizona, California, Georgia, Illinois, Maryland, Massachusetts, Nevada, New Mexico
2020-08-25
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
125
California, Florida, Indiana, Louisiana, Massachusetts, Michigan, Minnesota, Missouri
2020-08-25
By invitation
Homology Medicines, Inc
Observational
21
Massachusetts, New York
2020-08-19
Active, closed
Cerliponase Alfa Observational Study in the US
NCT04476862Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
BioMarin Pharmaceutical
Observational
35
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts
2020-08-19
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
477
California, Illinois, Indiana, Massachusetts, New Jersey, New York, North Carolina, Texas
2020-08-18
Active, closed
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
NCT04227847Myelodysplastic Syndrome, Acute Myeloid Leukemia
DrugsVenclexta·Azacitidine·Venetoclax
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
170
Alabama, California, Colorado, Kansas, Kentucky, Massachusetts, Michigan, Missouri
2020-08-07
Active, closed
Incyte Corporation
Phase 2
112
Alabama, Arizona, California, Colorado, Illinois, Kansas, Maryland, Massachusetts
2020-08-03
Active, closed
Genentech, Inc.
Phase 1
498
California, Connecticut, Florida, Massachusetts, New York, Oklahoma, Pennsylvania
2020-07-29
Active, closed
Celgene
Phase 2
276
California, Colorado, Connecticut, Illinois, Iowa, Kansas, Maryland, Massachusetts
2020-07-14
Recruiting
HighLife SAS
Not applicable
30
Arizona, California, Georgia, Massachusetts, Minnesota, New York, Pennsylvania, South Carolina
2020-07-14
By invitation
Cervical Interbody Implant Study
NCT04689854Degenerative Disc Disease, Cervical Spinal Instability
NuVasive
Observational
150
California, Connecticut, Massachusetts, Missouri, North Carolina, Ohio, Virginia
2020-07-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Alabama, Arkansas, California, Florida, Indiana, Kentucky, Massachusetts, Michigan
2020-07-06
Active, closed
GlaxoSmithKline
Phase 1
107
California, Massachusetts, Texas
2020-06-25
Active, closed
Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC
NCT04295811Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia
Lucid Diagnostics, Inc.
Not applicable
784
Colorado, District of Columbia, Florida, Illinois, Louisiana, Maryland, Massachusetts, Michigan
2020-06-18
Active, closed
Sanofi
Phase 3
337
California, Colorado, Florida, Massachusetts, North Carolina, Tennessee, Texas
2020-06-16
Active, closed
Eli Lilly and Company
Phase 1
71
California, Colorado, Illinois, Massachusetts, Ohio, Pennsylvania, Texas
2020-06-11
Recruiting
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
DrugsSigvotatug vedotin·Keytruda·Cisplatin·Carboplatin
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
1,006
Alaska, Arkansas, California, Florida, Illinois, Indiana, Kansas, Massachusetts
2020-06-08
Active, closed
GlaxoSmithKline
Phase 1/2
106
Georgia, Massachusetts, Michigan, Wisconsin
2020-06-08
Active, closed
Autolus Limited
Phase 1/2
153
California, Colorado, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts
2020-06-03
Active, closed
AstraZeneca
Phase 2
452
Maryland, Massachusetts, New York, Texas
2020-06-03
Recruiting
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
NCT04429542Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung
DrugPembrolizumab
Bicara Therapeutics
Phase 1
473
California, Florida, Massachusetts, New York, North Carolina, Ohio, Pennsylvania, Rhode Island
2020-06-01
Recruiting
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
NCT04256317Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
DrugsVenclexta·Azacitidine·Venetoclax
Taiho Oncology, Inc.
Phase 2/3
316
California, Connecticut, Florida, Georgia, Massachusetts, New Jersey, New York, North Carolina
2020-05-21
Active, closed
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
NCT04349436Merkel Cell Carcinoma, Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Cancer
Replimune, Inc.
Phase 1/2
69
Arizona, California, Colorado, Florida, Massachusetts, Minnesota, Missouri, New York
2020-05-15
Active, closed
2019-06 TRISCEND Study
NCT04221490Tricuspid Valve Regurgitation, Heart Valve Diseases, Cardiovascular Diseases
Edwards Lifesciences
Not applicable
228
California, Georgia, Illinois, Massachusetts, Michigan, New York, Oregon, Pennsylvania
2020-05-06
Active, closed
AstraZeneca
Phase 3
818
Arizona, California, Florida, Kansas, Maryland, Massachusetts, Minnesota, Missouri
2020-04-16
Active, closed
Eisai Inc.
Phase 1
31
Florida, Massachusetts, Missouri, Nevada, Tennessee
2020-04-01
Recruiting
CERAMENT™| Bone Void Filler Device Registry
NCT04244942Orthopedic Disorder
BONESUPPORT AB
Observational
300
Arizona, Florida, Indiana, Kentucky, Massachusetts, New York, North Carolina, Ohio
2020-03-30
Active, closed
BeOne Medicines
Phase 1
437
California, Illinois, Kansas, Massachusetts, Minnesota, Nebraska, New Jersey, New York
2020-03-24
Recruiting
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
NCT04094610Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
DrugRepotrectinib
Turning Point Therapeutics, Inc.
Phase 1/2
75
California, Colorado, Florida, Georgia, Maine, Massachusetts, Missouri, New Jersey
2020-03-12
Recruiting
Ascentage Pharma Group Inc.
Phase 1
144
California, Florida, Massachusetts, North Carolina, Ohio, Washington
2020-03-02
Active, closed
Immunocore Ltd
Phase 1/2
410
California, Colorado, District of Columbia, Florida, Illinois, Iowa, Massachusetts, New Jersey
2020-02-25
Active, closed
Genetix Biotherapeutics Inc.
Phase 3
35
Alabama, District of Columbia, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Texas
2020-02-14
By invitation
Global Utilization And Registry Database for Improved heArt preservatioN
NCT04141605Heart Diseases, Heart Failure, Heart Defects, Congenital
Paragonix Technologies
Observational
3,000
California, District of Columbia, Florida, Indiana, Kansas, Massachusetts, Michigan, New York
2020-02-14
Active, closed
Loxo Oncology, Inc.
Phase 3
291
Alabama, California, Georgia, Illinois, Massachusetts, Michigan, New York, Ohio
2020-02-11
Active, closed
Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi
NCT04042025Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III, SMA
DrugsOnasemnogene Abeparvovec-xioi·Zolgensma
Novartis Gene Therapies
Phase 3
85
California, Colorado, Illinois, Maryland, Massachusetts, Michigan, Missouri, New York
2020-02-10
Active, closed
Daiichi Sankyo
Phase 1
115
California, Connecticut, Florida, Maryland, Massachusetts, Missouri, Pennsylvania, Texas
2020-02-10
Active, closed
Boston Scientific Corporation
Not applicable
166
California, Florida, Georgia, Idaho, Illinois, Kansas, Massachusetts, Michigan
2020-01-30
Active, closed
Hoffmann-La Roche
Phase 2/3
325
California, Massachusetts, New York, North Carolina, Tennessee, Texas, Washington
2020-01-29
Active, closed
BeOne Medicines
Phase 3
955
Arizona, Arkansas, Colorado, Florida, Massachusetts, Michigan, Minnesota, Mississippi
2020-01-16
Active, closed
Takeda
Phase 3
354
California, Florida, Illinois, Maryland, Massachusetts, Tennessee, Virginia
2020-01-10
By invitation
Linguaflex, Inc.
Not applicable
80
Massachusetts, West Virginia, Wisconsin
2020-01-10
Active, closed
Hoffmann-La Roche
Phase 2
23
Colorado, District of Columbia, Massachusetts, Missouri, Ohio
2020-01-09
Active, closed
Regeneron Pharmaceuticals
Phase 1/2
95
California, District of Columbia, Florida, Massachusetts, New York, Pennsylvania, Texas
2020-01-07
Active, closed
USWM CT, LLC
Phase 2
103
California, Colorado, Florida, Illinois, Iowa, Massachusetts, Michigan, Minnesota
2019-12-31
Active, closed
Kite, A Gilead Company
Phase 1
40
Illinois, Massachusetts, Wisconsin
2019-12-23
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 1
161
Massachusetts, Texas
2019-12-20
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
450
Arizona, California, District of Columbia, Kentucky, Maryland, Massachusetts, Nebraska, New Hampshire
2019-12-19
Recruiting
Merck Sharp & Dohme LLC
Observational
1,065
Arizona, California, District of Columbia, Kentucky, Maryland, Massachusetts, Nebraska, New Hampshire
2019-12-19
Active, closed
InSightec
Not applicable
14
California, Florida, Massachusetts, Minnesota, New York
2019-12-19
Active, closed
CStone Pharmaceuticals
Phase 3
534
California, Maryland, Massachusetts, New York
2019-12-13
Active, closed
Cold Agglutinin Disease Real World Evidence Registry
NCT05791708Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)
RECORDATI GROUP
Observational
429
Alabama, California, District of Columbia, Georgia, Illinois, Iowa, Massachusetts, Michigan
2019-12-12
Active, closed
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
NCT04188548Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
DrugsImlunestrant·Alpelisib·Everolimus·Abemaciclib
Eli Lilly and Company
Phase 1
379
Arizona, Arkansas, California, Florida, Georgia, Indiana, Maryland, Massachusetts
2019-12-10
Active, closed
Alnylam Pharmaceuticals
Phase 3
655
California, District of Columbia, Georgia, Illinois, Massachusetts, Minnesota, New York, North Carolina
2019-11-26
Active, closed
OCS DCD Heart + CAP Continued Follow-Up
NCT05741723Heart Transplant
TransMedics
Observational
276
California, Connecticut, Florida, Georgia, Illinois, Indiana, Massachusetts, Minnesota
2019-11-26
Active, closed
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
NCT04013685Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Leukemia
DrugOrca-T
Orca Biosystems, Inc.
Phase 1
155
California, Colorado, Florida, Georgia, Illinois, Kansas, Massachusetts, Michigan
2019-11-21
Active, closed
Apple Heart & Movement Study
NCT04198194Prevention
Apple Inc.
Observational
500,000
Massachusetts
2019-11-14
Active, closed
Phoenix Molecular Designs
Phase 1/2
61
Arizona, California, Florida, Illinois, Massachusetts, Michigan, Ohio, Texas
2019-11-14
Active, closed
Fujifilm Pharmaceuticals U.S.A., Inc.
Phase 1
96
Arizona, Colorado, Massachusetts, New York, Ohio, Texas, Wisconsin
2019-11-14
Recruiting
Apple Women's Health Study
NCT04196595Menstrual Cycle, Ovulation, Menstruation, Polycystic Ovary Syndrome
Apple Inc.
Observational
500,000
Massachusetts
2019-11-14
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Illinois, Iowa, Kentucky, Massachusetts, Minnesota, New Jersey, New York, North Carolina
2019-11-13
Active, closed
AbbVie
Phase 1/2
218
California, Florida, Illinois, Massachusetts, Michigan, Minnesota, New York, North Carolina
2019-11-06
Recruiting
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
NCT04065399Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia
DrugsCobicistat·Revumenib
Syndax Pharmaceuticals
Phase 1/2
447
California, Colorado, Florida, Georgia, Illinois, Iowa, Massachusetts, Missouri
2019-11-05
Active, closed
Bristol-Myers Squibb
Phase 3
461
Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, New Hampshire, Ohio
2019-11-05
Active, closed
Boehringer Ingelheim
Phase 1
71
Massachusetts, North Carolina, Tennessee, Texas
2019-11-04
Active, closed
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
163
Arizona, District of Columbia, Florida, Indiana, Maryland, Massachusetts, Minnesota, New York
2019-11-04
Active, closed
Daiichi Sankyo
Phase 1/2
247
Colorado, Florida, Massachusetts, Michigan, Missouri, New Jersey, New York, Tennessee
2019-11-03
Active, closed
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
NCT04036682Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
DrugZipalertinib
Cullinan Therapeutics Inc.
Phase 1/2
284
California, Florida, Massachusetts, Michigan, New Jersey, New York, Ohio, Oregon
2019-10-31
By invitation
Rigel Pharmaceuticals
Phase 3
90
California, District of Columbia, Maryland, Massachusetts, Nevada, Washington
2019-10-30
Active, closed
Linnaeus Therapeutics, Inc.
Phase 1/2
200
California, Connecticut, Massachusetts, New Mexico, New York, Pennsylvania, Texas
2019-10-21
Active, closed
Chiesi USA, Inc.
Observational
5,050
California, Delaware, Florida, Idaho, Maryland, Massachusetts, Michigan, Missouri
2019-10-16
Recruiting
Cellectis S.A.
Phase 1/2
52
California, Colorado, Illinois, Massachusetts, New York, Pennsylvania, Tennessee, Texas
2019-10-14
Active, closed
GlaxoSmithKline
Phase 1/2
208
Georgia, Indiana, Massachusetts, Michigan, Wisconsin
2019-10-07
Active, closed
Celgene
Phase 1/2
424
Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota, New Jersey
2019-09-30
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,064
California, Colorado, Florida, Georgia, Illinois, Kansas, Kentucky, Massachusetts
2019-09-26
Active, closed
CARsgen Therapeutics Co., Ltd.
Phase 1/2
105
Arizona, California, Colorado, Florida, Massachusetts, Minnesota, Tennessee, Texas
2019-09-25
Active, closed
Applied Therapeutics, Inc.
Phase 3
675
California, Florida, Illinois, Massachusetts, Mississippi, Missouri, New York, Ohio
2019-09-20
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, New Jersey, New York
2019-09-18
Active, closed
Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury
NCT03992404Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
DrugXeomin
Merz Pharmaceuticals GmbH
Phase 3
603
Alabama, Arkansas, California, Connecticut, Florida, Massachusetts, Missouri, New York
2019-09-16
Active, closed
Sequana Medical N.V.
Not applicable
110
Arizona, California, Massachusetts, Minnesota, North Carolina, Pennsylvania, South Carolina, South Dakota
2019-09-16
Active, closed
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
NCT04067336Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia
DrugsZiftomenib·Itraconazole·Midazolam
Kura Oncology, Inc.
Phase 1/2
263
Arizona, California, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota
2019-09-12
Recruiting
Morphic Medical Inc.
Not applicable
264
Arizona, District of Columbia, Florida, Georgia, Louisiana, Massachusetts, Michigan, Minnesota
2019-09-09
Active, closed
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT03844048Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
DrugsVenclexta·Venetoclax
AbbVie
Phase 3
165
Arizona, California, Illinois, Massachusetts, Michigan, New Hampshire, Washington
2019-09-06
Active, closed
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
NCT03993873Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
Turning Point Therapeutics, Inc.
Phase 1
95
California, Colorado, Illinois, Massachusetts, Michigan, Missouri, Ohio, Texas
2019-09-05
Active, closed
Janssen Research & Development, LLC
Phase 1
701
California, Florida, Massachusetts, Michigan, Missouri, New York, Oregon, Pennsylvania
2019-09-04
Active, closed
BeOne Medicines
Phase 3
510
California, Illinois, Massachusetts, Michigan, Nevada, New York, Oregon, Pennsylvania
2019-08-20
Active, closed
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
NCT04044859Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer
USWM CT, LLC
Phase 1
120
Florida, Massachusetts, Missouri, New York, North Carolina, Oklahoma, Tennessee, Texas
2019-08-20
Active, closed
USWM CT, LLC
Phase 2
52
California, Colorado, Florida, Illinois, Maryland, Massachusetts, Michigan, Missouri
2019-08-13
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
345
Arizona, California, Colorado, Connecticut, Florida, Massachusetts, Michigan, Minnesota
2019-08-12
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
NCT04064060Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
DrugLuspatercept
Celgene
Phase 3
665
California, Florida, Illinois, Massachusetts, Michigan, New York, Ohio, Pennsylvania
2019-08-12
Active, closed
Novartis Pharmaceuticals
Phase 3
253
Georgia, Massachusetts, North Carolina, Tennessee, Texas
2019-07-26
Active, closed
Citadel Embolization Device Study
NCT04057352Unruptured Wide-neck Aneurysms
Stryker Neurovascular
Not applicable
150
California, Colorado, Florida, Illinois, Indiana, Kansas, Kentucky, Massachusetts
2019-07-18
Active, closed
Long Term Extension Study in Patients With Primary Hyperoxaluria
NCT04042402Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases
DrugDcr-Phxc
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Phase 3
75
California, Massachusetts, Minnesota, New York
2019-07-09
Active, closed
Dizal Pharmaceuticals
Phase 1/2
315
California, Colorado, Florida, Massachusetts, Michigan, New York, Ohio, Virginia
2019-07-09
Active, closed
AstraZeneca
Phase 3
587
California, Florida, Kansas, Kentucky, Massachusetts, Nevada, New York, Ohio
2019-07-02
Active, closed
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
DrugIbrutinib
Novartis Pharmaceuticals
Phase 1/2
217
California, Florida, Illinois, Kansas, Massachusetts, Pennsylvania, Tennessee, Texas
2019-06-26
Active, closed
AstraZeneca
Phase 2
247
California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, New York, Oregon
2019-06-25
Active, closed
Exelixis
Phase 3
855
California, Florida, Georgia, Illinois, Maine, Maryland, Massachusetts, Michigan
2019-06-25
Active, closed
AbbVie
Phase 1
124
Illinois, Kentucky, Massachusetts, Ohio, Oregon, Pennsylvania, Washington
2019-06-24
Active, closed
Bristol-Myers Squibb
Phase 3
437
District of Columbia, Georgia, Massachusetts, Pennsylvania, South Carolina
2019-06-21
Recruiting
Surgimab
Phase 3
300
California, Florida, Massachusetts, Pennsylvania
2019-06-17
Active, closed
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
NCT03899792Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
DrugSelpercatinib
Eli Lilly and Company
Phase 1/2
36
California, Colorado, Florida, Massachusetts, Minnesota, New York, Ohio, Pennsylvania
2019-06-13
Active, closed
Syntrix Biosystems, Inc.
Phase 1
77
Florida, Massachusetts, Minnesota, New York, Texas
2019-06-12
Active, closed
Janssen Research & Development, LLC
Phase 3
2,517
California, Colorado, Connecticut, Florida, Georgia, Illinois, Louisiana, Massachusetts
2019-06-11
By invitation
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
NCT03999801Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
AbbVie
Phase 2
865
Arizona, California, Maryland, Massachusetts, Nevada, Pennsylvania, Tennessee, Texas
2019-05-31
Recruiting
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
NCT03808922Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
Ansun Biopharma, Inc.
Phase 3
274
California, Illinois, Iowa, Kansas, Maryland, Massachusetts, Minnesota, Missouri
2019-05-23
Active, closed
Nuvaira, Inc.
Not applicable
464
Alabama, Arizona, California, Florida, Illinois, Kentucky, Massachusetts, Michigan
2019-05-23
Recruiting
Immatics US, Inc.
Phase 1/2
375
California, Colorado, Florida, Illinois, Massachusetts, New York, Ohio, Pennsylvania
2019-05-14
Active, closed
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
NCT03253263Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity, Intraventricular Hemorrhage, Retinopathy of Prematurity (ROP)
OHB Neonatology Ltd.
Phase 2
295
Arkansas, California, Florida, Illinois, Indiana, Kentucky, Louisiana, Massachusetts
2019-05-09
Active, closed
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
NCT03891953Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer
DrugSpartalizumab
Novartis Pharmaceuticals
Phase 1
98
Massachusetts, Tennessee
2019-05-07
Active, closed
AstraZeneca
Phase 3
810
California, District of Columbia, Florida, Kansas, Kentucky, Massachusetts, Missouri, North Carolina
2019-04-16
Active, closed
Blueprint Medicines Corporation
Phase 2
251
Alabama, Arizona, California, Florida, Georgia, Illinois, Kansas, Massachusetts
2019-04-16
Active, closed
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
NCT03941379Choroidal Melanoma, Indeterminate Lesions of Eye
Aura Biosciences
Observational
63
Arizona, California, Massachusetts, Michigan, Minnesota, New York, Oregon, Pennsylvania
2019-03-27
Active, closed
Agios Pharmaceuticals, Inc.
Phase 2
20
California, Massachusetts
2019-03-20
Active, closed
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT03845166Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
DrugsZanzalintinib·Avelumab·Tecentriq·Atezolizumab
Exelixis
Phase 1
325
California, Florida, Georgia, Iowa, Kansas, Maine, Maryland, Massachusetts
2019-03-20
Active, closed
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
NCT03860272Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer
DrugsBalstilimab·Botensilimab
Agenus Inc.
Phase 1
499
Arizona, California, Colorado, Connecticut, Florida, Massachusetts, New York, Oregon
2019-03-20
Recruiting
Imugene Limited
Phase 1
135
Florida, Georgia, Maryland, Massachusetts, Minnesota, New York, Rhode Island, Texas
2019-03-11
Recruiting
Aptose Biosciences Inc.
Phase 1/2
240
Alabama, California, Connecticut, Florida, Georgia, Massachusetts, North Carolina, Ohio
2019-03-11
Active, closed
Troriluzole in Adult Participants With Spinocerebellar Ataxia
NCT03701399Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3
DrugTroriluzole
Biohaven Pharmaceuticals, Inc.
Phase 3
299
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2019-03-08
Active, closed
Durvalumab and Tremelimumab for Pediatric Malignancies
NCT03837899Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
DrugDurvalumab
AstraZeneca
Phase 1/2
50
Maryland, Massachusetts, New York, Oklahoma, South Carolina
2019-03-07
Active, closed
Hoffmann-La Roche
Phase 3
1,000
Colorado, Connecticut, Massachusetts, North Carolina, Pennsylvania, Texas
2019-02-28
Active, closed
Acerta Pharma BV
Phase 3
984
California, Indiana, Kansas, Kentucky, Louisiana, Maryland, Massachusetts, New York
2019-02-25
Recruiting
Travere Therapeutics, Inc.
Phase 1/2
39
Colorado, Florida, Illinois, Indiana, Maine, Massachusetts, New York, North Carolina
2019-01-22
Recruiting
Persevere Therapeutics Inc.
Phase 1
80
Illinois, Kansas, Massachusetts, Pennsylvania
2019-01-14
Active, closed
AstraZeneca
Phase 2
367
California, District of Columbia, Maryland, Massachusetts, Minnesota, New York, Pennsylvania, Washington
2019-01-09
Active, closed
Viewray Inc.
Not applicable
133
California, Florida, Massachusetts, Michigan, Missouri, New Hampshire, New York, Oregon
2019-01-01
Active, closed
AstraZeneca
Phase 1/2
243
Arizona, Maryland, Massachusetts, Michigan, Missouri, Texas, Virginia
2018-12-21
Active, closed
Idorsia Pharmaceuticals Ltd.
Phase 3
107
Alabama, California, Florida, Illinois, Iowa, Massachusetts, Michigan, Pennsylvania
2018-12-18
Active, closed
Merck Sharp & Dohme LLC
Phase 2
329
Arizona, California, Colorado, Georgia, Kentucky, Maryland, Massachusetts, Michigan
2018-12-12
Active, closed
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
NCT03228667Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma
DrugsPD-L1 t-haNK·Avelumab·Atezolizumab·Durvalumab
ImmunityBio, Inc.
Phase 2
40
Alaska, Arkansas, California, Florida, Indiana, Iowa, Kentucky, Massachusetts
2018-12-11
Active, closed
TransMedics
Observational
458
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2018-12-10
Active, closed
TReatment of Pulmonary Hypertension Group II Study
NCT03611270Pulmonary Hypertension (PH) Due to Left Heart Disease
SoniVie Inc.
Not applicable
15
California, Massachusetts
2018-11-30
Active, closed
Eli Lilly and Company
Phase 2/3
393
Arizona, Arkansas, California, Colorado, Florida, Georgia, Indiana, Massachusetts
2018-11-26
Recruiting
Medtronic Terminate AF Study
NCT03546374Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation
Medtronic Cardiac Surgery
Not applicable
160
California, Connecticut, Indiana, Massachusetts, Michigan, Missouri, Ohio, Pennsylvania
2018-11-15
Active, closed
Medtronic Cardiovascular
Not applicable
150
Arizona, California, Connecticut, Florida, Georgia, Iowa, Massachusetts, Michigan
2018-10-30
Active, closed
AbbVie
Phase 3
265
Arizona, California, Colorado, Florida, Kentucky, Maryland, Massachusetts, Michigan
2018-10-22
Active, closed
Exelixis
Phase 3
187
California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kentucky, Massachusetts
2018-10-05
Active, closed
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
NCT03634540Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC), Kidney Cancer, Renal Cancer
DrugsBelzutifan·Cabozantinib
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
118
California, Florida, Massachusetts, Michigan, Tennessee, Texas, Washington
2018-09-27
Active, closed
Edwards Lifesciences
Not applicable
101
California, Colorado, District of Columbia, Florida, Georgia, Indiana, Kansas, Massachusetts
2018-09-18
Active, closed
CynosureLutronic
Not applicable
41
Massachusetts
2018-09-13
Active, closed
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
NCT03393884Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
DrugsIMNN-001·Paclitaxel·Carboplatin
Imunon
Phase 1/2
130
Alabama, California, Florida, Massachusetts, Missouri, New Jersey, New York, Oklahoma
2018-09-05
Active, closed
Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency
NCT03636438Ornithine Transcarbamylase (OTC) Deficiency
Ultragenyx Pharmaceutical Inc
Observational
11
Colorado, Massachusetts, New York, Ohio
2018-08-30
Active, closed
Hoffmann-La Roche
Phase 3
257
Illinois, Massachusetts, Pennsylvania
2018-08-16
Active, closed
Spark Therapeutics, Inc.
Observational
29
Massachusetts, Mississippi, Missouri, Oregon, Pennsylvania, Virginia
2018-08-14
Active, closed
C. R. Bard
Not applicable
213
Alabama, California, Connecticut, Iowa, Kentucky, Louisiana, Maryland, Massachusetts
2018-08-07
Active, closed
X-linked Hypophosphatemia Disease Monitoring Program
NCT03651505X-linked Hypophosphatemia, Hypophosphatemic Rickets
Ultragenyx Pharmaceutical Inc
Observational
782
Alabama, California, Colorado, Connecticut, Illinois, Indiana, Maryland, Massachusetts
2018-07-16
Recruiting
Astellas Institute for Regenerative Medicine
Phase 1
42
Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Mississippi
2018-07-13
Active, closed
ERG Components in Schizophrenia and Bipolar Disorder Type I
NCT03788811Schizophrenia, Bipolar I Disorder
diaMentis Inc.
Observational
300
California, Florida, Massachusetts, New Jersey, New York, Texas
2018-07-05
Active, closed
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
NCT03505320Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer, Pharmacokinetics of Oxaliplatin
DrugsFolinic acid·Zolbetuximab·Fluorouracil·Leucovorin
Astellas Pharma Global Development, Inc.
Phase 2
143
California, Illinois, Massachusetts, New York
2018-06-29
Active, closed
Exelixis
Phase 3
837
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Maryland, Massachusetts
2018-06-10
Active, closed
Evaluation of the GORE PV1 Device in Patients With Pulmonary Valve Dysfunction
NCT03441971Heart Defects, Congenital, Tetralogy of Fallot, Pulmonary Valve Insufficiency, Pulmonary Valve Stenosis
W.L.Gore & Associates
Not applicable
15
Illinois, Massachusetts, Ohio
2018-06-07
Active, closed
Inovio Pharmaceuticals
Phase 1/2
52
California, Florida, Georgia, Massachusetts, Michigan, New Jersey, New York, North Carolina
2018-05-31
Active, closed
Hoffmann-La Roche
Phase 3
927
California, Florida, Illinois, Massachusetts, Michigan, Missouri, New York, Ohio
2018-05-28
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
890
Alabama, Massachusetts, Minnesota, New York, Ohio, Oklahoma, Tennessee, Texas
2018-05-21
Active, closed
Extended Access of Momelotinib in Adults With Myelofibrosis
NCT03441113Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
GlaxoSmithKline
Phase 2
237
Arizona, California, Colorado, Florida, Georgia, Maryland, Massachusetts, Minnesota
2018-05-03
Active, closed
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
50
Maryland, Massachusetts, Michigan, Pennsylvania, Tennessee, Texas, Utah
2018-05-02
Recruiting
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
DrugPetosemtamab
Merus B.V.
Phase 1/2
560
California, Colorado, Florida, Georgia, Massachusetts, Michigan, Missouri, New York
2018-05-02
Active, closed
Multi-Center Study of Sensory Stimulation to Improve Brain Function
NCT03556280Alzheimer Disease, Cognitive Impairment, Mild Cognitive Impairment, Dementia Alzheimers
Cognito Therapeutics, Inc.
Not applicable
60
Florida, Massachusetts, New Jersey
2018-04-24
Active, closed
Pyruvate Kinase Deficiency Global Longitudinal Registry
NCT03481738Pyruvate Kinase Deficiency
Agios Pharmaceuticals, Inc.
Observational
500
Arizona, Arkansas, California, Georgia, Massachusetts, Michigan, North Carolina, Pennsylvania
2018-04-23
Recruiting
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
DrugsMevrometostat·Xtandi·Itraconazole·Enzalutamide
Pfizer
Phase 1
453
Arizona, California, Connecticut, Kansas, Kentucky, Maryland, Massachusetts, Nebraska
2018-04-17
Active, closed
The BEAR III Trial for Bridge-Enhanced ACL (Anterior Cruciate Ligament) Restoration
NCT03348995Anterior Cruciate Ligament Injury, Anterior Cruciate Ligament Rupture
Miach Orthopaedics
Not applicable
250
California, Florida, Georgia, Louisiana, Maryland, Massachusetts, New Jersey, Rhode Island
2018-04-17
Active, closed
AbbVie
Phase 2
156
Colorado, Florida, Georgia, Illinois, Massachusetts, New Jersey, New York, North Carolina
2018-04-02
Recruiting
The PREDICT Registry:
NCT03448926DCIS, Stage 0 Breast Cancer, Ductal Breast Carcinoma In Situ
PreludeDx
Observational
3,000
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2018-02-27
Active, closed
InSightec
Not applicable
92
California, Florida, Maryland, Massachusetts, Minnesota, New York, Ohio, Pennsylvania
2018-02-09
Active, closed
PARTNER 3 Trial - Mitral Valve in Valve
NCT03193801Mitral Valve Insufficiency, Mitral Valve Disease, Mitral Valve Regurgitation, Heart Failure
Edwards Lifesciences
Not applicable
53
Georgia, Illinois, Massachusetts, Minnesota, Missouri, New York, Oregon, Texas
2018-02-01
Active, closed
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
NCT03401385Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer
DrugDato-DXd
Daiichi Sankyo Co., Ltd.
Phase 1
890
California, District of Columbia, Georgia, Maryland, Massachusetts, New York, Tennessee, Texas
2018-01-31
Active, closed
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
NCT03386513Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
DrugIMGN632
AbbVie
Phase 1/2
179
Alabama, Arizona, California, Florida, Maryland, Massachusetts, New York, North Carolina
2018-01-02
Recruiting
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
NCT03394365Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant
DrugTabelecleucel
Pierre Fabre Medicament
Phase 3
115
California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Maryland, Massachusetts
2017-12-29
Recruiting
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
NCT03328078Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
DrugsEmavusertib·Ibrutinib
Curis, Inc.
Phase 1/2
152
Arizona, California, Connecticut, Florida, Illinois, Massachusetts, Minnesota, Nebraska
2017-12-28
Active, closed
AstraZeneca
Phase 2
528
California, District of Columbia, Illinois, Maryland, Massachusetts, Missouri, New York, Pennsylvania
2017-12-18
Active, closed
Early Feasibility Study of the RelayBranch Thoracic Stent-Graft System
NCT03214601Thoracic Aorta Aneurysm, Aneurysm, Ruptured, Aortic Aneurysm
Bolton Medical
Not applicable
30
California, Florida, Georgia, Maryland, Massachusetts, Missouri, New York, North Carolina
2017-12-04
Active, closed
Genentech, Inc.
Phase 1
181
Colorado, Massachusetts, New York, Tennessee
2017-11-24
Active, closed
BeiGene
Phase 3
590
Georgia, Illinois, Massachusetts, Missouri, Nevada, New Jersey, New York, North Carolina
2017-10-31
Active, closed
Daiichi Sankyo
Phase 1
312
California, Georgia, Massachusetts, Michigan, New York, Ohio, Pennsylvania, Tennessee
2017-10-30
Recruiting
Apollomics Inc.
Phase 2
497
California, Florida, Massachusetts, North Carolina, Pennsylvania, Wisconsin
2017-09-27
Active, closed
ModernaTX, Inc.
Phase 1
161
California, District of Columbia, Florida, Massachusetts, New York, Ohio, Pennsylvania, Texas
2017-08-14
Active, closed
Savolitinib vs. Sunitinib in MET-driven PRCC.
NCT03091192Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Urologic Neoplasms
DrugsSavolitinib·Sunitinib
AstraZeneca
Phase 3
60
California, Georgia, Illinois, Iowa, Massachusetts, Missouri, New York, Tennessee
2017-07-25
Active, closed
Novartis Pharmaceuticals
Phase 2
29
Massachusetts
2017-07-04
Active, closed
Cellectis S.A.
Phase 1
29
California, Florida, Illinois, Massachusetts, New York, Pennsylvania, Texas
2017-06-19
Active, closed
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
NCT03229200Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease
DrugIbrutinib
Pharmacyclics Switzerland GmbH
Phase 4
297
California, Georgia, Illinois, Kentucky, Massachusetts, Michigan, Nevada, New Jersey
2017-05-22
Active, closed
Pfizer
Phase 3
296
Florida, Massachusetts, New York, Tennessee, Washington
2017-04-27
Active, closed
Bolton Medical
Not applicable
50
California, Connecticut, Georgia, Indiana, Iowa, Maryland, Massachusetts, Missouri
2017-04-17
Active, closed
Bristol-Myers Squibb
Phase 3
1,314
Alaska, California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Michigan
2017-03-24
Active, closed
AbbVie
Phase 1
163
California, Illinois, Massachusetts, North Carolina, Tennessee, Texas, Virginia
2017-02-22
Active, closed
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
NCT03069469Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor
DrugVimseltinib
Deciphera Pharmaceuticals, LLC
Phase 1/2
120
California, Colorado, Florida, Massachusetts, New York, Oregon, Tennessee
2017-02-16
Active, closed
Persona Partial Knee Clinical Outcomes Study
NCT03034811Osteoarthritis, Avascular Necrosis, Traumatic Arthritis, Conditional Tibial Condyle or Plateau Fractures
Zimmer Biomet
Not applicable
757
California, Colorado, Illinois, Indiana, Massachusetts, Michigan, New Mexico, South Carolina
2017-02-08
Active, closed
DBV Technologies
Phase 3
300
Arkansas, California, Colorado, Illinois, Maryland, Massachusetts, New York, North Carolina
2017-01-23
Active, closed
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
NCT02682511Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic
DrugIfetroban
Cumberland Pharmaceuticals
Phase 2
34
Arizona, California, Florida, Maryland, Massachusetts, Nebraska, New York, Pennsylvania
2017-01
Active, closed
Ribociclib (LEE011) Rollover Study for Continued Access
NCT02934568Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
DrugRibociclib
Novartis Pharmaceuticals
Phase 2
22
Alabama, Massachusetts, Michigan, New York, Tennessee
2016-12-15
Active, closed
Genentech, Inc.
Phase 1
200
Massachusetts, New York, Tennessee
2016-12-13
Active, closed
Eli Lilly and Company
Phase 1
100
Arkansas, California, Colorado, Massachusetts, Michigan, New York
2016-11-14
Active, closed
Celgene
Phase 1/2
466
Arizona, Arkansas, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan
2016-10-14
Active, closed
Eisai Inc.
Phase 3
1,069
California, Florida, Illinois, Kansas, Louisiana, Maryland, Massachusetts, Michigan
2016-10-13
Active, closed
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
NCT02864992Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
DrugTepotinib
EMD Serono Research & Development Institute, Inc.
Phase 2
337
California, Colorado, Florida, Georgia, Illinois, Indiana, Maryland, Massachusetts
2016-09-13
Recruiting
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
NCT02584244Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer
Lumicell, Inc.
Phase 1/2
66
Massachusetts
2016-08-04
Recruiting
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
NCT02744677Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration
Edwards Lifesciences
Not applicable
108
Alabama, Arkansas, California, Colorado, Georgia, Kentucky, Massachusetts, Minnesota
2016-07-05
Recruiting
Collection and Distribution of Biospecimens for Novel Research Uses
NCT03848962Cancer, Healthy, Gastrointestinal Complication, Autoimmune Diseases
iSpecimen Inc
Observational
10,000
Alabama, Massachusetts
2016-06-30
Active, closed
Celgene
Phase 1/2
130
California, Connecticut, Illinois, Massachusetts, New York, Texas
2016-06-03
Active, closed
Janssen Research & Development, LLC
Phase 1
751
California, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri
2016-05-24
Active, closed
Hoffmann-La Roche
Phase 1/2
69
California, Colorado, Georgia, Illinois, Maryland, Massachusetts, Missouri, New York
2016-05-03
Recruiting
Boston Scientific Corporation
Observational
100
Alabama, Idaho, Massachusetts, New Hampshire, New Jersey
2016-05
Active, closed
Bridge-Enhanced ACL Repair vs ACL Reconstruction
NCT02664545Anterior Cruciate Ligament Tear
Miach Orthopaedics
Not applicable
100
Massachusetts
2016-04
Active, closed
DS-3201b in Participants With Lymphomas
NCT02732275Lymphoma, Malignant, Non-hodgkin Lymphoma
DrugValemetostat Tosylate
Daiichi Sankyo Co., Ltd.
Phase 1
100
California, Connecticut, Georgia, Massachusetts, New Jersey, New York, North Carolina, Ohio
2016-03-31
Active, closed
AstraZeneca
Phase 1/2
264
Georgia, Maryland, Massachusetts, Michigan, Missouri, Ohio, Pennsylvania
2016-03-17
Active, closed
MedImmune LLC
Phase 1/2
383
Alabama, Arizona, California, Colorado, Florida, Illinois, Maryland, Massachusetts
2016-02-22
Active, closed
Acerta Pharma BV
Phase 1/2
24
California, Massachusetts, New York, Washington
2016-01-25
Active, closed
Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product
NCT02698579Cerebral Adrenoleukodystrophy (CALD), Adrenoleukodystrophy (ALD), X-Linked Adrenoleukodystrophy (X-ALD)
Genetix Biotherapeutics Inc.
Observational
64
California, Massachusetts, Minnesota
2016-01-22
Active, closed
Bayer
Phase 1/2
154
California, Florida, Massachusetts, New York, Ohio, Pennsylvania, Tennessee, Texas
2015-12-16
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Arizona, California, Georgia, Illinois, Kansas, Massachusetts, Michigan, Minnesota
2015-11-02
Active, closed
AstraZeneca
Phase 3
1,126
California, Colorado, Connecticut, Florida, Georgia, Kentucky, Massachusetts, Michigan
2015-11-02
Active, closed
MedImmune LLC
Phase 2
433
Arizona, California, Connecticut, Florida, Indiana, Massachusetts, New York, North Carolina
2015-10-19
Recruiting
Karyopharm Therapeutics Inc
Phase 1/2
300
Arizona, California, Colorado, Massachusetts, Nebraska, New Jersey, New York, North Carolina
2015-10
Active, closed
Taiho Oncology, Inc.
Phase 1/2
253
Alabama, Arizona, California, Connecticut, Georgia, Illinois, Maryland, Massachusetts
2015-07-14
Active, closed
Novartis Pharmaceuticals
Phase 1
57
Arizona, Massachusetts, Pennsylvania
2015-05-27
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
370
Colorado, Illinois, Massachusetts, New York, North Dakota, South Dakota, Texas
2015-03-19
Active, closed
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
NCT02381886Advanced Malignancies That Harbor IDHR132 Mutations
Novartis Pharmaceuticals
Phase 1
166
Massachusetts, New York, Texas
2015-03-06
Active, closed
Acerta Pharma BV
Phase 2
124
Florida, Illinois, Massachusetts, New Jersey, New York, Texas, Washington
2015-03-02
Active, closed
Edwards EVOQUE Eos MISCEND Study
NCT02718001Mitral Valve Regurgitation (Degenerative or Functional)
Edwards Lifesciences
Not applicable
123
California, Georgia, Illinois, Indiana, Massachusetts, New Jersey, New York, Ohio
2015-02-06
Active, closed
A Trial of Vigil for Participants With Ovarian Cancer
NCT02346747Ovarian Cancer, Ovarian Neoplasms
Gradalis, Inc.
Phase 2
92
Alabama, California, Florida, Georgia, Kentucky, Maine, Massachusetts, Michigan
2015-02
By invitation
Registry of Patients With Hypophosphatasia
NCT02306720Hypophosphatasia (HPP)
Alexion Pharmaceuticals, Inc.
Observational
1,571
Colorado, Connecticut, Florida, Georgia, Maryland, Massachusetts, Minnesota, Missouri
2015-01-20
Active, closed
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
NCT02912949Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
DrugBispecific
Partner Therapeutics, Inc.
Phase 2
250
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Michigan
2015-01
Active, closed
Bridge-Enhanced ACL Repair-Safety Study (BEAR Trial)
NCT02292004Anterior Cruciate Ligament Injury, Anterior Cruciate Ligament Tear
Miach Orthopaedics
Not applicable
20
Massachusetts
2015-01
Active, closed
Karyopharm Therapeutics Inc
Phase 2
244
Arizona, California, Florida, Illinois, Kentucky, Massachusetts, New Jersey, New York
2014-11
Active, closed
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
NCT02264678Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
DrugsSaruparib·Olaparib·Durvalumab·Carboplatin
AstraZeneca
Phase 1
358
California, Massachusetts, New York, Pennsylvania
2014-10-31
Active, closed
AstraZeneca
Phase 1
344
Georgia, Massachusetts, New York, Pennsylvania, Tennessee
2014-08-05
Active, closed
Eli Lilly and Company
Phase 3
669
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2014-07-22
Active, closed
Registry for Participants With Short Bowel Syndrome
NCT01990040Short Bowel Syndrome
Shire
Observational
1,806
Massachusetts
2014-06-23
Active, closed
PERIGON Pivotal Trial
NCT02088554Aortic Stenosis
Medtronic Cardiac Surgery
Not applicable
1,312
California, Colorado, Connecticut, Florida, Georgia, Maryland, Massachusetts, Michigan
2014-05-12
Active, closed
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
NCT03301168Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
DrugsBPX-501 T cells·Rimiducid
Bellicum Pharmaceuticals
Phase 1/2
120
California, District of Columbia, Georgia, Massachusetts, New York, Oregon, Texas, Washington
2014-04
Active, closed
Eli Lilly and Company
Phase 1
198
Arkansas, California, Massachusetts, Minnesota, New York, North Carolina, Oregon, Pennsylvania
2014-03-10
Recruiting
Boston Scientific Corporation
Observational
1,500
California, Colorado, Florida, Idaho, Illinois, Indiana, Massachusetts, Missouri
2014-03-04
Active, closed
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
NCT02029443Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Prolymphocytic Leukemia
DrugAcalabrutinib
Acerta Pharma BV
Phase 1/2
306
Massachusetts, New York, Ohio, Texas, Utah, Washington
2014-01-30
Active, closed
AbbVie
Phase 1
237
Arizona, California, Colorado, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2014-01-15
Active, closed
Bolton Medical
Not applicable
158
Alabama, Arizona, Connecticut, Florida, Georgia, Illinois, Iowa, Massachusetts
2013-11-23
Active, closed
Novartis Pharmaceuticals
Phase 1/2
259
California, Florida, Massachusetts, Tennessee, Texas, Washington
2013-10-22
Active, closed
AstraZeneca
Phase 3
510
Colorado, Florida, Georgia, Illinois, Louisiana, Massachusetts, New York, North Carolina
2013-09-25
Active, closed
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
DrugIbrutinib
Janssen Research & Development, LLC
Phase 3
539
California, Connecticut, Georgia, Illinois, Indiana, Kansas, Kentucky, Massachusetts
2013-09-09
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Alabama, California, Colorado, Connecticut, Florida, Illinois, Maryland, Massachusetts
2013-09-03
Active, closed
Novartis Pharmaceuticals
Phase 3
240
Alabama, California, Florida, Massachusetts, Michigan, New Jersey, Pennsylvania, Utah
2013-07-26
Recruiting
Lysosomal Acid Lipase (LAL) Deficiency Registry
NCT01633489Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease, Wolman Disease, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2
Alexion Pharmaceuticals, Inc.
Observational
300
Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota
2013-05-30
Recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183Atypical Hemolytic-Uremic Syndrome
Alexion Pharmaceuticals, Inc.
Observational
3,000
Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Missouri, North Carolina
2013-03-18
Active, closed
Baxalta now part of Shire
Phase 1/2
30
California, Colorado, Georgia, Illinois, Massachusetts, Minnesota, New York, Oregon
2013-02-11
Active, closed
InSightec
Not applicable
10
Massachusetts, Washington
2012-08
Active, closed
Optetrak Knee System Post Market Clinical Follow-Up
NCT05788757Knee Arthroplasty, Total
Exactech
Observational
4,588
Massachusetts, Nevada, South Carolina
2011-06-01
Active, closed
Medtronic Cardiac Rhythm and Heart Failure
Not applicable
64
Alabama, California, Florida, Illinois, Massachusetts, Minnesota, Texas, Wisconsin
2011-06
Recruiting
Gaucher Disease Outcome Survey (GOS)
NCT03291223Gaucher Disease
Shire
Observational
1,257
Massachusetts
2010-12-29
Active, closed
AstraZeneca
Phase 2
162
California, Florida, Indiana, Massachusetts, New York, Oregon
2010-02-04
Rows per page Showing 1501–1830 of 1830
Previous 2 3 4
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/state/massachusetts?page=4

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,830 of those studies with a site in Massachusetts.

How many clinical trials are recruiting in Massachusetts?

953 of the 1,830 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 43 have not yet opened recruitment, 776 are active but closed to new participants, and 58 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.